| 24.58 0.6 (2.5%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.58 | 1-year : | 34.55 |
| Resists | First : | 25.32 | Second : | 29.58 |
| Pivot price | 23.89 |
|||
| Supports | First : | 20.38 | Second : | 17.32 |
| MAs | MA(5) : | 23.82 |
MA(20) : | 22.72 |
| MA(100) : | 19.66 |
MA(250) : | 18.08 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.3  |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 76.6 |
| RSI | RSI(14): 71.2 |
|||
| 52-week | High : | 25.32 | Low : | 10.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CBLL ] has closed below upper band by 18.2%. Bollinger Bands are 48.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.7 - 24.8 | 24.8 - 24.9 |
| Low: | 23.51 - 23.61 | 23.61 - 23.72 |
| Close: | 24.41 - 24.59 | 24.59 - 24.78 |
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Mon, 31 Aug 2026
CeriBell, Inc. - Common Stock (CBLL) Stock Price, News, Quote & History - FinancialContent
Tue, 25 Aug 2026
Ceribell (NASDAQ: CBLL) CRO sale covers RSU tax bill only - Stock Titan
Tue, 25 Aug 2026
Ceribell (CBLL) insider offloads 1,852 shares via RSU tax and 10b5-1 sales - Stock Titan
Tue, 25 Aug 2026
Ceribell (CBLL) CFO sells 1,521 shares to cover taxes - Stock Titan
Tue, 25 Aug 2026
Ceribell (CBLL) CEO sells shares to cover RSU taxes - Stock Titan
Mon, 10 Aug 2026
Ceribell Reports Second Quarter 2026 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 87.7 (%) |
| Shares Short | 2,020 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | -1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | -64.8 % |
| Operating Margin | -71.2 % |
| Return on Assets (ttm) | -23.4 % |
| Return on Equity (ttm) | -44 % |
| Qtrly Rev. Growth | 32.5 % |
| Gross Profit (p.s.) | 2.36 |
| Sales Per Share | 2.65 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -13.97 |
| PEG Ratio | 0 |
| Price to Book value | 7.31 |
| Price to Sales | 9.25 |
| Price to Cash Flow | -17.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|